Your browser doesn't support javascript.
loading
Predicting transcription factor activity using prior biological information.
Yashar, William M; Estabrook, Joseph; Holly, Hannah D; Somers, Julia; Nikolova, Olga; Babur, Özgün; Braun, Theodore P; Demir, Emek.
Afiliação
  • Yashar WM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
  • Estabrook J; Division of Oncologic Sciences, Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
  • Holly HD; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97239, USA.
  • Somers J; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
  • Nikolova O; Department of Molecular and Medical Genetics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
  • Babur Ö; Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR 97239, USA.
  • Braun TP; Department of Molecular and Medical Genetics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
  • Demir E; Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR 97239, USA.
iScience ; 27(3): 109124, 2024 Mar 15.
Article em En | MEDLINE | ID: mdl-38455978
ABSTRACT
Dysregulation of normal transcription factor activity is a common driver of disease. Therefore, the detection of aberrant transcription factor activity is important to understand disease pathogenesis. We have developed Priori, a method to predict transcription factor activity from RNA sequencing data. Priori has two key advantages over existing methods. First, Priori utilizes literature-supported regulatory information to identify transcription factor-target gene relationships. It then applies linear models to determine the impact of transcription factor regulation on the expression of its target genes. Second, results from a third-party benchmarking pipeline reveals that Priori detects aberrant activity from 124 single-gene perturbation experiments with higher sensitivity and specificity than 11 other methods. We applied Priori and other top-performing methods to predict transcription factor activity from two large primary patient datasets. Our work demonstrates that Priori uniquely discovered significant determinants of survival in breast cancer and identified mediators of drug response in leukemia.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article